Jesús Loarce-Martos

Jesús Loarce-Martos

Auto-generated profile, based on publicly available information

Jesús Loarce-Martos

Division of Rheumatology, Hospital Ramón y Cajal , Madrid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 September 2020 in Rheumatology International
Verified
Journal Article
Open access
PDF file
JLJesús Loarce-Martos
Jesús Loarce-Martos
AGAntía García-Fernández
Antía García-Fernández
FLFernando López-Gutiérrez
Fernando López-Gutiérrez
VGVerónica García-García
Verónica García-García
LCLaura Calvo-Sanz
Laura Calvo-Sanz
MVMónica Vázquez-Díaz
Mónica Vázquez-Díaz
The objective of this study is to describe the characteristics and outcomes of rheumatic and musculoskeletal disease (RMD) patients who were treated with rituximab and had suspected or confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this descriptive study, RMD patients who were treated with rituximab in the last 12 months at the Rheumatology Department of our hospital were screened for SARS-CoV-2 infection via telephone interview and a comprehensive review of clinical health records (01/02/2020–26/05/2020). Those with probable or confirmed SARS-CoV-2 infection were included. In total, 76 patients were screened. Of these, 13 (17.1%) had suspected or confirmed SARS-CoV-2 infection. With regard to these 13 patients, the median age at coronavirus disease (COVID-19) diagnosis was 68 years (range 28–76 years) and 8 (61.5%) were female. Five patients had rheumatoid arthritis, three had systemic vasculitis, two had Sjögren syndrome, and two had systemic lupus erythematosus. Additionally, seven patients (53.8%) had pulmonary involvement secondary to RMD. Eight patients (61.5%) developed severe disease leading to hospitalization, and seven developed bilateral pneumonia and respiratory insufficiency. Of the eight hospitalized patients, five (62.5%) fulfilled the acute respiratory distress syndrome criteria and three developed a critical disease and died. Our cohort had a high rate of severe disease requiring hospitalization (61.5%), with bilateral pneumonia and hyperinflammation leading to a high mortality rate (23.1%). Treatment with rituximab should be considered a possible risk factor for unfavorable outcomes in COVID-19 patients with RMD. However, further study is required to confirm this association.

24 December 2020 in Rheumatology
Verified
Journal Article
Closed access
JLJesus Loarce-Martos
Jesus Loarce-Martos
JLJames B Lilleker
James B Lilleker
MPMatthew Parker
Matthew Parker
NMNeil McHugh
Neil McHugh
HCHector Chinoy
Hector Chinoy
Objective: The current classification criteria for idiopathic inflammatory myopathy (IIM) retain PM as a major disease subgroup. However, evolution in the understanding of IIM has suggested that many of these patients could be better described as having an alternative diagnosis. In the present study, we apply the latest understanding of IIM subtyping to retrospectively review PM diagnoses in a large cohort of IIM patients. Methods: Within a previously reported cohort of 255 patients from a UK tertiary myositis clinic, 37 patients classified as PM according to both the EULAR/ACR IIM criteria and expert opinion were identified. Clinical data and complementary tests were reviewed, and consensus decisions regarding final classification were reached in each case. Results: Nine (9/37, 24.3%) patients remained classified as PM, 3.5% (9/255) of the original cohort; these PM patients were seronegative for myositis antibodies, responsive to immunosuppression, and in 4/7 (57.1%) patients where muscle biopsy was performed had HLA-1 upregulation and endomysial inflammatory infiltrates. Immune-mediated necrotizing myopathy (5/37, 13.5%) and connective tissue disease overlap myositis (7/37, 19%) were the main alternative diagnoses. The remaining patients were diagnosed as: unspecified myopathy (6/37, 16%), dermatomyositis (2/37, 5%), cancer-associated myopathy (3/37, 8.1%), and non-inflammatory myopathy (1/37, 3%, myofibrillar myopathy). Four patients (4/37, 10%) had insufficient data available to confidently reclassify. Conclusion: Our study confirms that PM can now be considered a rare IIM subgroup. A thorough examination, complete myositis autoantibody panel, and careful interpretation of the biopsy results is recommended to confirm the correct IIM sub-type.

17 December 2024 in Arthritis & Rheumatology
Verified
Journal Article
Open access
SFSara Faghihi‐Kashani
Sara Faghihi‐Kashani
AYAkira Yoshida
Akira Yoshida
FBFrancisca Bozan
Francisca Bozan
Giovanni ZanframundoGiovanni Zanframundo
Giovanni Zanframundo
DRDavide Rozza
Davide Rozza
TIthe Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators
the Classification Criteria for Anti‐Synthetase Syndrome Project participating investigators
Objective: Anti‐synthetase syndrome (ASSD) is a rare systemic autoimmune rheumatic disease (SARD) with significant heterogeneity and no shared classification criteria. We aimed to identify clinical and serological features associated with ASSD that may be suitable for inclusion in the data‐driven classification criteria for ASSD.Methods: We used a large, international, multicenter “Classification Criteria for Anti‐synthetase Syndrome” (CLASS) project database, which includes both patients with ASSD and controls with mimicking conditions, namely, SARDs and/or interstitial lung disease (ILD). The local diagnoses of ASSD and controls were confirmed by project team members. We employed univariable logistic regression and multivariable Ridge regression to evaluate clinical and serological features associated with an ASSD diagnosis in a randomly selected subset of the cohort.Results: Our analysis included 948 patients with ASSD and 1,077 controls. Joint, muscle, lung, skin, and cardiac involvement were more prevalent in patients with ASSD than in controls. Specific variables associated with ASSD included arthritis, diffuse myalgia, muscle weakness, muscle enzyme elevation, ILD, mechanic's hands, secondary pulmonary hypertension due to ILD, Raynaud phenomenon, and unexplained fever. In terms of serological variables, Jo‐1 and non–Jo‐1 anti‐synthetase autoantibodies, antinuclear antibodies with cytoplasmic pattern, and anti‐Ro52 autoantibodies were associated with ASSD. In contrast, isolated arthralgia, dysphagia, electromyography/magnetic resonance imaging/muscle biopsy findings suggestive of myopathy, inflammatory rashes, myocarditis, and pulmonary arterial hypertension did not differentiate between patients with ASSD and controls or were inversely associated with ASSD.Conclusion: We identified key clinical and serological variables associated with ASSD, which will help clinicians and offer insights into the development of data‐driven classification criteria for ASSD. image

10 February 2023 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
JLJesús Loarce-Martos
Jesús Loarce-Martos
LSLaura Calvo Sanz
Laura Calvo Sanz
SGSandra Garrote-Corral
Sandra Garrote-Corral
RGRubén Ballester González
Rubén Ballester González
RRRoberto Pariente Rodríguez
Roberto Pariente Rodríguez
GAGarbiñe Roy Ariño
Garbiñe Roy Ariño

10 June 2025 in Rheumatology
Verified
Journal Article
Closed access
ASAna Serrano-Combarro
Ana Serrano-Combarro
BABelén Atienza-Mateo
Belén Atienza-Mateo
AMAdrián Martín-Gutiérrez
Adrián Martín-Gutiérrez
JLJesús Loarce-Martos
Jesús Loarce-Martos
CDCésar Antonio Egües Dubuc
César Antonio Egües Dubuc
JSJuan C Sarmiento-Monroy
Juan C Sarmiento-Monroy
Objective: The objective of this study was to assess the effectiveness and safety of baricitinib (BARI) in interstitial lung disease associated with RA (RA-ILD) in clinical practice. Methods: : This was a national multicentre retrospective study of 72 RA-ILD patients treated with BARI. We analysed the following outcomes at baseline and at 3, 6, 12, 18 and 24 months, and at last follow-up: (i) dyspnea (modified Medical Research Council scale), (ii) forced vital capacity (FVC), (iii) diffusing capacity of the lungs for carbon monoxide (DLCO), (iv) chest high-resolution CT (HRCT), (v) arthritis activity (DAS28-ESR), and (vi) CS-sparing effect. Additionally, we analysed the safety data and performed a literature review up to December 2023. Results: We included 72 patients (52 women; mean (s.d.) age 68 (10) years). All patients had received DMARDs. The median [interquartile range (IQR)] ILD duration up to BARI initiation was 25 [13–63] months. The most frequent ILD patterns were usual interstitial pneumonia (n = 33; 49%) and non-specific interstitial pneumonia (n = 22; 32%). BARI was used in monotherapy in 43 (60%) patients and combined with conventional synthetic DMARDs in 29 (40%). Mean (s.d.) baseline values of FVC and DLCO (% predicted) were 86 (28) and 69 (20), respectively. After a median [IQR] follow-up of 32 [13–65] months, dyspnea, FVC, DLCO and HRCT improved or stabilized in 90%, 88%, 65% and 72%, respectively. The mean DAS28-ESR improved from 4.29 to 2.99, and the median prednisone dose was reduced from 5 to 2.5 mg/day. Relevant adverse events were uncommon. Conclusion: BARI may be a useful and safe alternative in both pulmonary and joint disease in RA-ILD patients, even in refractory cases.

1 October 2020 in Vasa
Verified
Journal Article
Closed access
JCJuan José Soto Castillo
Juan José Soto Castillo
JLJesús Loarce-Martos
Jesús Loarce-Martos
JBJosé Miguel Blanc-Molina
José Miguel Blanc-Molina
Aortitis is a rare entity that may cause fever of unknown origin. This entity has a wide various etiologies, which main cause is rheumatologic, but not only. Iatrogenia has also been described, including chemotherapy and supporting treatment (like granulocyte-colony stimulating factor in oncological patients. The evidence in favour of this pharmacological link is growing. The differential diagnosis of fever, in febrile neutropenia setting, can be difficult to itemize.